J&J Slashes 2026 EPS Guidance by ~5% Despite Steady Sales Outlook
JNJ sits 59% above its 52-week low of $164.23.
Summary
Johnson & Johnson cut its 2026 adjusted operating EPS guidance to $10.86-$11.01 from $11.50-$11.65, a roughly 5% reduction, while trimming adjusted EPS to $10.96-$11.11 from $11.60-$11.75. The sales forecast remains unchanged at $100.8B-$101.4B, indicating margin pressure is the culprit. This follows the July 29 8-K that disclosed a $1B Firefly Bio acquisition and a $785M Sail Biomedicines collaboration, alongside a guidance cut — the newswire now provides the specific EPS figures. The magnitude of the cut is material for a $640B market-cap company, signaling higher costs or integration expenses are weighing on profitability. With STELARA sales already down 55% in Q2, the lowered earnings outlook suggests biosimilar headwinds and investment spending are biting harder than expected.
At the time of this announcement, JNJ was trading at $260.61 on NYSE in the Life Sciences sector, with a market capitalization of approximately $639.9B. The 52-week trading range was $164.23 to $274.90. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Binance News.